Poly Medicure , a leading medical device manufacturer, has announced a strategic acquisition that promises to reshape the landscape of cardiology care in India. The company has secured a 90% stake in the Netherlands-based PendraCare Group for an enterprise value of Rs 188.5 crore, with plans to acquire the remaining 10% by 2030.

Cost Reduction and Market Access

Managing Director Himanshu Baid highlighted the significant impact this acquisition is expected to have on the Indian healthcare market. By leveraging local manufacturing capabilities, Poly Medicure aims to reduce the costs of critical cardiology catheters by 25-30%. This move is particularly crucial as most of these devices are currently imported, making them expensive for Indian patients.

The deal also provides Poly Medicure with immediate access to the lucrative US and European markets. PendraCare's existing manufacturing setup in Europe and its regulatory approvals will be key assets in this expansion.

Product Portfolio and Market Potential

The acquisition brings a range of essential cardiology products under Poly Medicure's umbrella, including:

• Angiographic catheters
• Guiding catheters
• Diagnostic catheters

These devices are critical components in angiography and angioplasty procedures. With approximately 20 lakh angiographies performed annually in India, the market potential is substantial.

Financial Projections and Synergies

Poly Medicure is optimistic about the financial outcomes of this acquisition:

• Expected synergy of €3-4 million between the companies over the next two to three years
• Projected improvement in margins to over 25%
• Anticipated domestic business growth exceeding 30%

Market Response and Challenges

The market has responded positively to the news, with Poly Medicure's shares closing 1.47% higher at Rs 2,025.00. However, the company faces potential challenges from GST rationalization, which is set to take effect on September 22.

Investor Relations

In related news, Poly Medicure has scheduled investor meetings in the coming weeks. The company will hold virtual and physical one-on-one meetings with representatives from Invesco Asset Management (India) Private Limited and PineBridge Investments. These meetings demonstrate the company's commitment to maintaining open communication with investors following this significant acquisition.

This strategic move by Poly Medicure not only strengthens its position in the medical device market but also aligns with the broader goal of making critical healthcare more accessible and affordable in India. As the company integrates PendraCare's operations and expands its global footprint, the medical device landscape in India and beyond is poised for significant transformation.

Poly Medicure , a prominent player in the medical devices sector, has made headlines with a significant block trade and an announcement of an upcoming investor meeting.

Block Trade Details

The company recently completed a substantial block trade on the National Stock Exchange (NSE). The transaction involved approximately 116,048 shares changing hands at a price of Rs. 2,004.90 per share, amounting to a total value of Rs. 23.27 crores.

Upcoming Investor Meeting

In a separate development, Poly Medicure has informed the stock exchanges about an upcoming investor meeting. According to the company's regulatory filing:

• Date: Thursday, 11th September, 2025
• Participant: PineBridge Investments
• Venue: Physical meeting at the Company's Registered Office

The company emphasized that no Unpublished Price Sensitive Information will be shared during the meeting, adhering to regulatory compliance.

Management's Statement

Avinash Chandra, Company Secretary of Poly Medicure, stated in the filing, "The above schedule is subject to changes which may happen due to exigencies on the part of the Analysts/Investors/the Company."

About Poly Medicure Ltd.

Poly Medicure Limited is a leading medical device manufacturer with a global presence. The company operates manufacturing facilities in Faridabad, Haryana, and has been expanding its product portfolio in recent years.

Investor Considerations

While the block trade indicates significant investor interest in Poly Medicure, potential investors should note that past performance does not guarantee future results. As always, it is advisable to conduct thorough research and consider one's financial goals before making investment decisions.

The upcoming investor meeting may provide further insights into the company's strategies and outlook, which could be of interest to current and prospective shareholders alike.